Davion HealthCare Plc

What Davion HealthCare Plc does

Davion HealthCare Plc is an Irish-domiciled medical technology company that designs, develops, and distributes non-invasive, at-home testing devices intended to provide early identification of medical anomalies associated with serious health conditions including breast cancer, circulation disorders linked to diabetes and vascular disease, and testicular cancer. The company's portfolio centers on temperature-sensitive diagnostic pads and color-based indicators that consumers apply at home, with results delivered through companion mobile applications or web portals. Its target customers are health-conscious individual consumers seeking proactive monitoring between clinical visits, alongside regional distribution partners and—potentially—healthcare providers and payors seeking to reduce routine clinic burden through remote screening.

The lead product, BreastCheck, is an FDA- and CE-registered at-home breast health screening test that uses two soft temperature-sensitive pads to detect subtle changes in breast temperature, with results available via mobile app or online portal. FootFlow compares toe temperatures between the left and right foot to flag circulation issues, and Testic is a color-based testicular health test producing results in under 15 minutes. A fourth product, ThermaDerm, sits in the pipeline. Together the portfolio represents a horizontally-oriented platform of self-administered screening tools rather than a single deep diagnostic franchise, and the underlying science (thermo-comparison and color-based indicators) is straightforward rather than algorithmic.

Until June 2026 Davion operated a capital-light, licensing-led model, partnering with third-party manufacturers and regional distributors to scale internationally while generating licensing fees and royalties. In June 2026 the company terminated its existing global licensing arrangement for BreastCheck and announced a shift to direct commercialization, concurrently entering agreements to acquire a controlling interest in UK-based Solar Medical and Chemical Limited as its principal UK distribution platform and 100% of Humanoskan Ltd (a medical-technology IP holder) for $60 million ($10 million cash plus $50 million in Davion shares at $13.00 per share). The company is pursuing a direct listing on Nasdaq Global Market under ticker DAVI (F-1 declared effective November 2025) and has announced a proposed £100 million corporate bond programme at a 10.5% fixed coupon across three series to be listed on the Vienna Stock Exchange MTF platform, expected to launch August 2026. Leadership comprises CEO Jack Kaye, CCO David Over, CFO Andreas Ttofi, and a board chaired by Sir Eric Peacock with significant financial-services pedigree.

Name

Davion HealthCare Plc

Legal name

Davion Healthcare Plc

Website

https://davionhealthcare.com

Company type

Public

Founded year

2024

Operating status

Operating

Short description

Davion HealthCare Plc is an Irish medical technology company that designs, develops, and distributes non-invasive, FDA- and CE-registered home testing devices for early detection of breast, circulation, and testicular anomalies, currently transitioning from a licensing model to direct commercialization across the EU and US.

Ownership category

akta.pro rank

Product category

Home Preventive Health Diagnostics

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYHLAHACAL

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

SECONDARYHLAHAOAF

Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics

SECONDARYCRADAMAK

Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests)

Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

SECONDARYHLALAAAE

At-Home Lab Testing & Diagnostics-Integrated Virtual Care

Healthcare & Life Sciences/Telehealth Platforms/Direct-to-Consumer Virtual Care Platforms

Keywords

• Non-invasive home diagnostics
• At-home medical testing
• Preventive health monitoring
• Early cancer detection
• Temperature-sensitive screening

Headquarters

HQ city

Cork

HQ country

Ireland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Others

Revenue model

1. Product Licensing and Royalties: Capital-light licensing model where Davion designs and registers proprietary monitoring tools while partnering with third parties for manufacturing and distribution, generating licensing fees and royalty revenue.
2. Direct Product Sales: Post-transition to direct commercialization model, selling products directly to consumers through owned distribution platform (Solar Medical and Chemical Limited in UK), with greater control over product strategy and customer relationships.
3. Acquisition-Driven Growth: Building revenue through strategic acquisitions of complementary products and businesses as part of broader healthcare platform strategy.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Davion HealthCare Plc designs, develops, manufactures (via partners), and globally distributes non-invasive home testing medical devices that provide early-stage warnings of medical anomalies associated with serious health conditions. Its flagship product BreastCheck is an FDA- and CE-registered at-home breast health screening test using temperature-sensitive pads, complemented by FootFlow for circulation monitoring and Testic for testicular health, with results delivered via mobile app and online portal.

Product overview

Davion HealthCare Plc operates a platform of non-invasive home testing medical devices for early-stage detection of medical anomalies. The core portfolio includes BreastCheck (FDA- and CE-registered at-home breast health screening using temperature-sensitive technology with companion mobile app), FootFlow (toe temperature comparison test for circulation monitoring), and Testic (testicular health monitoring). Results are delivered through companion mobile apps or web portals. The company has transitioned from a licensing-led model to direct commercialization with its own distribution infrastructure in the UK.

Differentiator

Problem solved

Functional benefit

Brands

• BreastCheck: FDA-registered at-home breast health screening test using thermosensitive patch technology with companion mobile app for early detection of potential breast anomalies.
• FootFlow
• Testic
• ThermaDerm

Products and services

• BreastCheck

Quantifiable outcome

• BreastCheck takes less than 15 minutes with instant results; FootFlow takes 10 minutes; Testic takes less than 15 minutes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Humanoskan Ltd (also referred to as Humanitieskan Ltd / Huma sikan Ltd)coreStrategic or Co-development Partner · 25 June 2026Davion Healthcare has entered into a share purchase agreement to acquire 100% of the issued share capital of Humanoskan Ltd, a medical technology company focused on proprietary healthcare products and intellectual property, for total consideration of $60 million ($10 million cash + $50 million in Davion shares). The acquisition is intended to strengthen Davion's portfolio of non-invasive remote health monitoring solutions and expand its healthcare IP portfolio.
• Solar Medical and Chemical LimitedcoreStrategic or Co-development Partner · 22 June 2026Davion Healthcare has entered into an agreement to acquire a controlling interest in Solar Medical and Chemical Limited, a UK-based medical products distributor. Upon completion, Solar Medical is intended to become Davion's principal commercial and distribution platform in the United Kingdom, supporting its product portfolio including BreastCheck, FootFlow, and Testic.

Scale indicators5 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• LetsGetChecked: LetsGetChecked offers a broad portfolio of DTC at-home health tests with mobile-app results delivery and international distribution. Closely comparable to Davion's capital-light, multi-indication, app-enabled at-home testing model.
• Healthy.io: Healthy.io offers at-home smartphone-based diagnostic tests (notably urinalysis and kidney monitoring) with FDA clearance and digital results delivery. Directly comparable to Davion as a regulated, smartphone-integrated at-home diagnostics company targeting consumer-driven screening use cases.
• Everlywell: Everlywell sells DTC at-home lab testing kits across multiple indications with online results portals. Comparable to Davion's DTC channel, multi-indication product portfolio, and consumer-facing at-home health testing positioning.
• UE LifeSciences (iBreastExam): UE LifeSciences develops the iBreastExam portable, non-invasive breast lesion detection device for use in clinical and low-resource settings. Direct competitor to BreastCheck in non-invasive breast health screening technology.

Emerging players

• Tempdrop: Tempdrop builds wearable overnight temperature sensors for fertility and health tracking. Tangentially comparable to Davion through shared temperature-sensing technology and direct-to-consumer health monitoring positioning.
• Scanwell Health: Scanwell Health develops smartphone-based at-home diagnostic tests (e.g., UTI, kidney disease) with FDA clearance. Comparable to Davion's smartphone-integrated, regulated, at-home diagnostic testing approach.
• Cyrcadia Health: Cyrcadia Health is developing wearable, temperature-based breast health monitoring technology. Comparable to Davion's BreastCheck in the niche of non-invasive, temperature-based breast anomaly detection.

Broad incumbents

• Hologic: Hologic is a global leader in mammography and breast health diagnostics. Relevant as the established incumbent whose mammography franchise defines the screening standard Davion's BreastCheck is positioned against.
• iCAD: iCAD provides AI-powered breast cancer detection and risk assessment solutions used alongside mammography. A broader incumbent competing in breast health screening, representing the standard-of-care ecosystem Davion would need to displace or complement.
• Withings: Withings makes a broad portfolio of connected home health devices including connected thermometers, blood pressure monitors, and sleep/activity trackers. Comparable to Davion in the connected, non-invasive home health device category, though at much larger scale and across different indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Davion HealthCare Plc